IMV - IMV STOCK NEWS

IMV Inc. has appointed Andrew Hall as Chief Executive Officer and Director, effective January 1, 2022. Hall's leadership over the last five months is credited with refocusing the company on its immuno-oncology strengths. IMV is positioned to advance its development strategy, having recently achieved key milestones, including positive clinical data in two Phase 2 trials and submission of a Phase 2b protocol for ovarian cancer to the FDA. The company believes its DPX platform holds significant potential to provide differentiated cancer therapies as it moves into 2022.

IMV Inc. announced the final results from its Phase 2 basket clinical study evaluating maveropepimut-S (MVP-S) combined with KEYTRUDA® in patients with metastatic bladder cancer and MSI-H solid tumors. The study, involving 131 patients, showed promising clinical benefits, particularly in those previously treated with immune checkpoint inhibitors. The company plans to discuss follow-up studies with key opinion leaders. A comprehensive data set will be shared at an upcoming scientific conference, spotlighting MVP-S as a potential immune-educating therapy.

IMV Inc. (NASDAQ: IMV) has secured a US$25 million long-term debt facility led by Horizon Technology Finance Corporation (NASDAQ: HRZN). The company has accessed US$15 million immediately, with an additional US$10 million contingent on meeting a milestone. This financing bolsters funding for clinical development of IMV’s lead candidate, maveropepimut-S (MVP-S), and supports ongoing projects using their DPX technology platform. Proceeds will also settle existing loans, enhancing IMV's financial flexibility.

IMV Inc. has announced new translational data from the DeCidE1 study involving maveropepimut-S (MVP-S) for treating advanced ovarian cancer. These findings, to be presented at the ESMO-IO congress from December 8-10, 2021, indicate significant B cell involvement in clinical benefits from MVP-S. Key results include an Objective Response Rate (ORR) of 26.3% and a median overall survival of 19.9 months. The data illustrate the potential of MVP-S in creating robust anti-tumor immune responses, with future trials expected in 2022.

IMV Inc. announced that the first patient with HR+/HER2- breast cancer has been dosed with maveropepimut-S (MVP-S) as part of a Phase 1b clinical trial. This study aims to evaluate MVP-S in combination with an aromatase inhibitor, potentially improving treatment efficacy against a well-recognized resistance mechanism in breast cancer. Primary results are expected by the end of 2023, with the study anticipated to conclude in 2026. IMV's lead immunotherapy candidate, MVP-S, has previously shown promising anti-tumor responses.

IMV Inc. (NASDAQ: IMV) is set to present at the Piper Sandler Virtual Healthcare Conference, with a fireside chat scheduled for November 23, 2021, at 11:00 a.m. ET. This event precedes the main conference taking place from November 30 to December 2, 2021. The presentation will focus on IMV's innovative DPX platform, which is central to its immune-educating cancer therapies aimed at treating solid and blood cancers. A webcast of the chat will be available on IMV's website, allowing broader access to the company's advancements in cancer treatment.

IMV Inc. (NASDAQ: IMV) announced the retirement of Chief Financial Officer Pierre Labbé, effective March 31, 2022. Following his departure, Labbé will continue to consult to ensure a smooth transition. Interim CEO Andrew Hall lauded Labbé's contributions, stating that his financial guidance has positioned the company to reach crucial milestones, including the anticipated registration trials for MVP-S next year, based on promising early data. IMV is focused on advancing its DPX platform for developing cancer therapies, including MVP-S and DPX-SurMAGE.

IMV Inc. announced that translational data from its Phase 2 study of MVP-S in advanced ovarian cancer patients will be presented at the SITC Annual Meeting. Key findings show that MVP-S treatment resulted in significant T and B cell tumor infiltration and identified potential resistance mechanisms. The data suggest that immunogenic tumors respond better to MVP-S, providing insights for predicting treatment responses. IMV plans to initiate a Phase 2B study in 2022 to further assess MVP-S with cyclophosphamide.

IMV Inc. (NASDAQ: IMV) will hold a conference call on November 11, 2021 at 8:00 a.m. ET to discuss its third quarter 2021 financial and operational results. Analysts can join by dialing U.S. (866) 211-3204 or international (647) 689-6600, using conference ID 7079735. A live audio webcast will also be available and recorded for 30 days. IMV focuses on developing novel immune-educating cancer therapies using its proprietary DPX platform, targeting solid and blood cancers while minimizing side effects.